JP2022500456A5 - - Google Patents

Info

Publication number
JP2022500456A5
JP2022500456A5 JP2021514419A JP2021514419A JP2022500456A5 JP 2022500456 A5 JP2022500456 A5 JP 2022500456A5 JP 2021514419 A JP2021514419 A JP 2021514419A JP 2021514419 A JP2021514419 A JP 2021514419A JP 2022500456 A5 JP2022500456 A5 JP 2022500456A5
Authority
JP
Japan
Prior art keywords
crystal form
compound
cancer
chemical formula
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021514419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500456A (ja
JP7554030B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/057720 external-priority patent/WO2020053816A1/en
Publication of JP2022500456A publication Critical patent/JP2022500456A/ja
Publication of JP2022500456A5 publication Critical patent/JP2022500456A5/ja
Application granted granted Critical
Publication of JP7554030B2 publication Critical patent/JP7554030B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514419A 2018-09-14 2019-09-12 キナゾリン化合物及びその塩酸塩の結晶形 Active JP7554030B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862731500P 2018-09-14 2018-09-14
US62/731,500 2018-09-14
PCT/IB2019/057720 WO2020053816A1 (en) 2018-09-14 2019-09-12 Crystalline forms of a quinazole compound and its hydrochloride salts

Publications (3)

Publication Number Publication Date
JP2022500456A JP2022500456A (ja) 2022-01-04
JP2022500456A5 true JP2022500456A5 (cg-RX-API-DMAC10.html) 2022-09-22
JP7554030B2 JP7554030B2 (ja) 2024-09-19

Family

ID=69776732

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021513941A Pending JP2022500416A (ja) 2018-09-14 2019-09-12 がんを処置するためのキットおよび方法
JP2021514419A Active JP7554030B2 (ja) 2018-09-14 2019-09-12 キナゾリン化合物及びその塩酸塩の結晶形

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021513941A Pending JP2022500416A (ja) 2018-09-14 2019-09-12 がんを処置するためのキットおよび方法

Country Status (17)

Country Link
US (2) US20220040180A1 (cg-RX-API-DMAC10.html)
EP (2) EP3849557A4 (cg-RX-API-DMAC10.html)
JP (2) JP2022500416A (cg-RX-API-DMAC10.html)
KR (2) KR102802129B1 (cg-RX-API-DMAC10.html)
CN (2) CN112770758A (cg-RX-API-DMAC10.html)
AR (2) AR116406A1 (cg-RX-API-DMAC10.html)
AU (2) AU2019340598B2 (cg-RX-API-DMAC10.html)
BR (2) BR112021004527A2 (cg-RX-API-DMAC10.html)
CA (2) CA3110369A1 (cg-RX-API-DMAC10.html)
IL (2) IL281167A (cg-RX-API-DMAC10.html)
MX (2) MX2021002876A (cg-RX-API-DMAC10.html)
PH (2) PH12021550432A1 (cg-RX-API-DMAC10.html)
PY (2) PY1976957A (cg-RX-API-DMAC10.html)
SG (2) SG11202102006YA (cg-RX-API-DMAC10.html)
TW (2) TW202027750A (cg-RX-API-DMAC10.html)
UY (2) UY38375A (cg-RX-API-DMAC10.html)
WO (2) WO2020056156A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102802129B1 (ko) 2018-09-14 2025-05-02 한미약품 주식회사 퀴나졸린 화합물 및 이의 염산염의 결정 형태
CA3158733A1 (en) 2019-11-21 2021-05-27 Pilar Calvo Methods of treating small cell lung cancer with lurbinectedin formulations
CN114642728A (zh) * 2021-06-02 2022-06-21 德琪(浙江)医药科技有限公司 mTOR抑制剂的制药用途及其药物组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5069905B2 (ja) * 2003-01-21 2012-11-07 アプテュイト (ウエスト ラファイエット)、エルエルシー 新規な共結晶化
KR100735639B1 (ko) * 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
AU2006217738A1 (en) * 2005-02-26 2006-08-31 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
BRPI0712720A2 (pt) * 2006-05-31 2012-11-20 Abbott Lab compostos tiazàis como ligantes do receptor canabinàide e usos dos mesmos
EP2054393A1 (en) * 2006-07-28 2009-05-06 Synthon B.V. Crystalline erlotinib
ES2573931T3 (es) * 2007-02-21 2016-06-13 Natco Pharma Limited Nuevos polimorfismos de clorhidrato de erlotinib y método de preparación
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
KR101217526B1 (ko) * 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
KR101317809B1 (ko) * 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR101272613B1 (ko) * 2011-10-05 2013-06-10 한미사이언스 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
LT2964638T (lt) * 2013-03-06 2017-12-27 Astrazeneca Ab Epidermio augimo faktoriaus receptoriaus aktyvinančių mutacijų formų chinazolino inhibitoriai
WO2015154725A1 (zh) * 2014-04-11 2015-10-15 四川海思科制药有限公司 喹唑啉衍生物及其制备方法和在医药上的应用
US10308658B2 (en) * 2015-10-19 2019-06-04 Sunshine Lake Pharma Co., Ltd. Salt of EGFR inhibitor, crystalline form and uses thereof
CA3040348A1 (en) * 2016-10-19 2018-04-26 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating cancer
BR112019010020A2 (pt) 2016-11-17 2019-08-20 Univ Texas compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
KR102802129B1 (ko) 2018-09-14 2025-05-02 한미약품 주식회사 퀴나졸린 화합물 및 이의 염산염의 결정 형태

Similar Documents

Publication Publication Date Title
JP7396960B2 (ja) 5,10-メチレン-(6r)-テトラヒドロ葉酸のヘミ硫酸塩
ES2702450T3 (es) Derivados de la quinoxalina útiles como moduladores de la FGFR quinasa
JP6905662B2 (ja) 置換キノリン化合物の結晶形およびその医薬組成物
JP2020514271A5 (cg-RX-API-DMAC10.html)
AU2019218186B2 (en) Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof
JP2010525057A5 (cg-RX-API-DMAC10.html)
JP2008509948A5 (cg-RX-API-DMAC10.html)
JP2009515992A5 (cg-RX-API-DMAC10.html)
JP2018534289A5 (cg-RX-API-DMAC10.html)
CA2917096A1 (en) Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors
NZ739185A (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
JP2010523700A5 (cg-RX-API-DMAC10.html)
JP2018533608A (ja) 置換キノリン化合物の結晶形およびその医薬組成物
JP2012518598A5 (cg-RX-API-DMAC10.html)
JP2018529643A5 (cg-RX-API-DMAC10.html)
JP7554030B2 (ja) キナゾリン化合物及びその塩酸塩の結晶形
CN109311817B (zh) 取代的含氮芳环化合物及其应用
EP3101020A1 (en) Deuterated quinazolinone compound and pharmaceutical composition comprising same
JP5161072B2 (ja) オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
CN109476649B (zh) 五元杂环类化合物及其制备方法、药物组合物和用途
JP7770026B2 (ja) マンガン含有配位錯体の水性製剤の製造方法、製剤および処置方法
JP7018224B2 (ja) 尿素置換芳香族環結合ジオキシノキノリン系化合物、その調製方法および使用
RU2021110277A (ru) Наборы и способы для лечения онкологических заболеваний
CN106146478A (zh) 三嗪衍生物类间变性淋巴瘤激酶抑制剂
RU2605400C1 (ru) ПРОИЗВОДНЫЕ 1-(3-АМИНОФЕНИЛ)-6,8-ДИМЕТИЛ-5-(4-ИОД-2-ФТОР-ФЕНИЛАМИНО)-3-ЦИКЛОПРОПИЛ-1H,6H-ПИРИДО[4,3-d]ПИРИМИДИН-2,4,7-ТРИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ МЕК1/2